SEGMENTS (Tables)

9 Months Ended

Sep. 30, 2022

SEGMENTS [Abstract]

Summarized Financial Information Concerning Reportable Segments

Summarized financial information concerning reportable segments is shown in the following tables:

Three Months Ended September 30, 2022
	ADMA			Plasma Collection
	BioManufacturing			Centers			Corporate			Consolidated
Revenues	$	37,280,798		$	3,773,631		$	35,708		$	41,090,137
Cost of product revenue		27,883,046			3,550,450			-			31,433,496
Income (loss) from operations		297,310			(4,636,269	)		(4,977,774	)		(9,316,733	)
Interest and other expense, net		(3,023	)		(154	)		(5,579,594	)		(5,582,771	)
Net income (loss)		294,287			(4,636,423	)		(10,557,368	)		(14,899,504	)
Total assets		242,983,498			39,125,933			18,448,139			300,557,570
Depreciation and amortization expense		1,214,529			647,463			-			1,861,992

Three Months Ended September 30, 2021
	ADMA			Plasma Collection
	BioManufacturing			Centers			Corporate			Consolidated
Revenues	$	19,063,077		$	1,581,765		$	35,708		$	20,680,550
Cost of product revenue		18,695,783			1,599,430			-			20,295,213
Loss from operations		(7,456,129	)		(3,163,886	)		(3,817,061	)		(14,437,076	)
Interest and other expense, net		22,822			(1,597	)		(3,297,103	)		(3,275,878	)
Net loss		(7,433,307	)		(3,165,483	)		(7,114,164	)		(17,712,954	)
Total assets		189,019,883			22,273,264			27,347,259			238,640,406
Depreciation and amortization expense		1,064,757			356,233			1,174			1,422,164

Nine Months Ended September 30, 2022
	ADMA			Plasma Collection
	BioManufacturing			Centers			Corporate			Consolidated
Revenues	$	95,129,542		$	8,861,570		$	107,125		$	104,098,237
Cost of product revenue		74,383,948			8,626,208			-			83,010,156
Loss from operations		(4,423,228	)		(12,520,163	)		(16,363,147	)		(33,306,538	)
Interest and other expense, net		(70,084	)		(1,221	)		(13,624,483	)		(13,695,788	)
Loss on extinguishment of debt		-			-			(6,669,941	)		(6,669,941	)
Net loss		(4,493,312	)		(12,521,384	)		(36,657,571	)		(53,672,267	)
Capital expenditures		4,292,246			5,870,404			-			10,162,650
Depreciation and amortization expense		3,486,212			1,689,362			918			5,176,492

Nine Months Ended September 30, 2021
	ADMA			Plasma Collection
	BioManufacturing			Centers			Corporate			Consolidated
Revenues	$	48,832,000		$	5,620,633		$	107,125		$	54,559,758
Cost of product revenue		51,527,832			5,370,127			-			56,897,959
Loss from operations		(25,299,223	)		(7,928,946	)		(11,954,388	)		(45,182,557	)
Interest and other expense, net		(77,484	)		(2,349	)		(9,735,808	)		(9,815,641	)
Net loss		(25,376,707	)		(7,931,295	)		(21,690,196	)		(54,998,198	)
Capital expenditures		3,805,472			6,029,932			-			9,835,404
Depreciation and amortization expense		3,130,064			843,151			4,571			3,977,786

Net Revenues According to Geographic Area

Net revenues according to geographic area, based on the location of where the product is shipped, is as follows:

	Three Months Ended September 30,				Nine Months Ended September 30,
	2022		2021		2022		2021
United States	$	37,854,167	$	18,265,945	$	96,445,162	$	47,368,793
International		3,235,970		2,414,605		7,653,075		7,190,965
Total revenues	$	41,090,137	$	20,680,550	$	104,098,237	$	54,559,758